Are mutations in alpha-tropomyosin and cardiac troponin T associated with specific clinical phenotypes and sudden death risk in familial hypertrophic cardiomyopathy?
Patients with familial hypertrophic cardiomyopathy in a referral-center population
Presence of mutations in alpha-tropomyosin or cardiac troponin T
Prevalence of mutations, degree of hypertrophy, and incidence of sudden deathhard clinical
Mutations in cardiac troponin T and alpha-tropomyosin identify a subset of hypertrophic cardiomyopathy patients with mild hypertrophy but high risk for sudden death, highlighting the clinical utility of genetic testing.
Mutations in alpha-tropomyosin are a rare cause of familial hypertrophic cardiomyopathy, accounting for approximately 3 percent of cases. Mutations in cardiac troponin T account for approximately 15 percent of cases of familial hypertrophic cardiomyopathy in this referral-center population. These mutations are characterized by relatively mild and sometimes subclinical hypertrophy but a high incidence of sudden death. Genetic testing may therefore be especially important in this group.
Building similarity graph...
Analyzing shared references across papers
Loading...
Hugh Watkins
AstraZeneca (United Kingdom)
William J. McKenna
Statens Serum Institut
Ludwig Thierfelder
General Cardiology
New England Journal of Medicine
Harvard University
Howard Hughes Medical Institute
Brigham and Women's Hospital
Building similarity graph...
Analyzing shared references across papers
Loading...
Watkins et al. (Thu,) studied this question.
synapsesocial.com/papers/69d5721975589c71d767e4c1 — DOI: https://doi.org/10.1056/nejm199504203321603